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Introduction
One of the primary objects of the registry was to keep an
up-to-date list of living cases which had had bone sarcoma
and which could be considered as cured. It should be
remembered that the Registry was started for and by the
family of a patient under the care of the writer for a sup-
posed bone sarcoma. They wished and I wished to ascertain
the actual facts as to whether there were any living cured
cases of this disease and if there actually were, to ascertain
the methods of treatment by which these patients had been
cured. I was given a thousand dollars to pay my expenses in
obtaining the required facts.
My ﬁrst step (in August, 1920) was to address a circular
letter to the individual members of the American College
of Surgeons and to the surgical profession in general. The
advice of Dr. Ewing and Dr. Bloodgood was sought in
consultation. Through the kindness of my personal friends
in several earnest clinics, follow-up investigations were
started. In fact that gift of a thousand dollars made me and
many others work and soon led the Regents of the College
to add an aggregate of $8000 more, contributed from time
to time, in order to answer these two simple questions.
Now at the end of ﬁve years, only 17 cases of primary
malignant bone tumors have been collected which in our
opinion may be considered cured (Ewing’s tumor, 4
cases—osteogenic sarcoma, 13 cases).
In spite of all our efforts my patient died within the year
and autopsy showed that the supposed sarcoma was a
metastatic cancer of unknown origin. The chagrin of the
error in diagnosis was somewhat allayed when reports from
various clinics stimulated by our investigation began to
appear. Greenough, Simmons, and Harmer analyzing the
cases from the Massachusetts General Hospital and
Huntington Memorial Hospital, for instance, reported:
‘‘Perhaps the most surprising fact of the whole study is that
of 148 cases, sent in as possible bone sarcoma, only 68
could be considered in fact to be cases of malignant
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DOI 10.1007/s11999-009-1049-6newgrowth of bony origin; the remaining 82 cases proving
on more detailed study to be metastatic tumors of bone (29
cases), sarcoma primary in the soft parts (28 cases),
inﬂammatory conditions (11 cases), or tumors of a non-
sarcomatous type (14 cases).’’
It soon appeared that by-products were to be the result of
our industry rather than the intended product of obtaining
the answers to our simple questions. The Registry itself
was a by-product, for when our collection of cases could no
longer be of possible beneﬁt to my patient the Regents saw
that the same questions would be eternal. The friends of
future patients would always want to know of the living
cases and how they were cured. Five years have passed
since the ﬁrst circular letter went out and some of our by-
products may be listed as follows:
1. Many contributions to the medical literature on bone
tumors.
2. A more or less acceptable standard classiﬁcation,
presented and discussed in the form of a small book.
(Reprinted in Bull. Am. Col. of Surg., 1926, x, No. 1,
A.)
3. The impersonal proof of Dr. Bloodgood’s contention
that giant cell tumor is benign.
4. The impersonal proof that cases of giant cell tumor
may be cured by radiotherapy.
5. The diffusion of Dr. Mallory’s contention that benign
giant cell tumor is not a neoplasm but a faulty repair
phenomenon.
6. The impersonal proof that many of the cures from
combined treatment by surgery, mixed toxins, and
radium claimed by Dr. Coley are authentic.
7. The principle of co-operative education (concerning
rare diseases) among laboratories (the founding of
other Registries).
8. The possession by the American College of Surgeons
of collections of data on 100 standard benign giant
cell tumors, 100 standard osteogenic sarcomata of the
femur, 100 standard osteogenic sarcomata of other
bones, 50 standard cases of Ewing’s tumor. (These
data are neatly packed in trunk-like boxes available
for study by investigators or by pathologists or sur-
geons who see few bone tumor cases but who
occasionally must decide questions of life and limb.)
9. A principle suggested for the new Museum of the
College (and for other museums) of accumulation of
data on accepted standard clinical entities, in avail-
able form for intensive research and educational
study.
10. The idea that the Museum might become a sort of
patent ofﬁce of new clinical entities. A practical
example of this idea by submitting a collection of
over 50 cases of Ewing’s tumor.
11. The suggestion that the College should devote its
energies to the standardization of series of surgical
cases, asking from hospitals duplicate records of one
series after another. (For instance, a check on the
standardization of hospitals might be made in epit-
ome on the manner in which the cases of bone
sarcoma are registered since such registration tests
not only the apparatus of roentgenologist, pathologist,
and surgeon, but the education, cerebration, and
practical efﬁciency of the staff and perhaps even their
consciences.)
There are other by-products, but the true product of our
industry is small—only 17 cases of 5 year cures of pri-
mary, malignant tumors of bone on which the Committee
can agree even tentatively. And in these cases much
essential evidence is lacking. In ten of these for instance
the X-ray has been lost. The evidence on few of the 17 is
entirely convincing.
As to the treatment, all but 1 of the 17 had amputation
and that one had a local exploration followed by intensive
radium treatment and mixed toxins. Nine of the other 16
also had toxins. Eight also had radiation. In 8 cases these
treatments were combined. Seven had no other treatment
than amputation so far as we know.
I think the average surgeon will perhaps be content with
the two paragraphs above. He will continue to amputate in
doubtful cases if he thinks there is any possible chance that
no metastases have already occurred. He will ignore the
fact that the one radium and toxin cure probably represents
a greater percentage of cures among those where this
combination of treatments has been attempted than the
sixteen amputations represent to the vast number in which
surgery has failed.
We have many unknown factors: (1) How many
amputations have been done and failed? (2) How many
cases have there been in which the mixed toxins have been
thoroughly tried and failed with or without amputation? (3)
How many cases have received thorough radiation with or
without surgery.
We have few facts and can estimate as we please. The
answers are probably: (1) Very, very many. (2) A good
many. (3) Very few or even very, very few. And all this
guesswork must take into consideration that of all the cases
submitted to the Registry as sarcomata, the Committee
believes only a little over 50 per cent were actually
malignant primary tumors of bone!
Since the Registry was not quite 5 years old at the time
this set of 17 cases was agreed on by the Committee (June
1, 1925), the real use of the collection in answering our
question will not be attained for 5 years from that date. It
can then deal with cases of standard diagnoses agreed on
before the result is known. At present we can only say that
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1it is probable that an occasional case may be saved by
amputation or by amputation combined with toxins and
radium; and that in 1 atypical case of primary malignant
bone tumor with metastasis in the groin the patient
recovered after an exploratory operation and the postop-
erative use of Coley toxins and radium.
Will the reader please reconsider the last sentence and
bear in mind that these statements were made by the
Registrar of a Committee of the largest surgical society in
the world consisting of over 7,000 members, every one of
whom has been repeatedly solicited to register any case of
bone sarcoma in which the patient is living, whether cured,
under treatment, or moribund, and especially if cured
5 years ago!
And yet anyone in searching the literature will ﬁnd
many reports of cures and percentages of cures. Read again
the above quotation from Greenough, Simmons, and Har-
mer, and reﬂect on the percentage of erroneous diagnoses
compared with the percentage of cures.
However, the paragraph in italics does not give all our
optimism for it is boiled down to the coldest hardest facts.
We have other evidence that all of these therapeutic agents,
amputation, Coley toxins, and radium are effective in
greater or less degree. There are a few more cases
remaining well 5 years which we almost accept. There are
many 5 year cures in cases which we consider benign giant
cell tumor and a considerable number of cases of osteo-
genic sarcoma are nearing the 5 year limit. We are
conﬁdent that each year in the future the report of the
Registrar will be more favorable—particularly in regard to
the use of radiation.
The Committee of which I was Registrar will be abun-
dantly satisﬁed if they have succeeded in establishing a
moderately acceptable standard nomenclature and moder-
ately acceptable criteria of malignancy. To recommend an
absolute nomenclature or absolute criteria would be ridic-
ulous. Nevertheless, nomenclature and criteria must
precede statistics on therapeutics.
Part I.—Twenty-Five Criteria for Establishing
the Diagnosis of Osteogenic Sarcoma
Our list of 17 cured cases applies only to primary malig-
nant tumors of bone, that is, to our classes of osteogenic
sarcoma (13) and of Ewing’s tumor (4). Of the latter I shall
say little because there is at this writing an article in press
for the Archives of Surgery, by C. L. Conner which ana-
lyzes all our cases of Ewing’s tumor and really gives the
most up-to-date knowledge of this new entity. The four
5 year cures of Ewing’s tumor No. 185, No. 267, No. 348,
No. 398 will there be reported. They will also be reported
from the Memorial Hospital Clinic of New York by Coley
and some have already appeared in the literature in
Ewing’s articles. As will appear in Conner’s critical anal-
ysis, Ewing’s tumor is in a class by itself as far as prognosis
under radiation is concerned. It was this favorable response
to radiation which ﬁrst led Ewing to see that it was a
separate entity apart from true osteogenic sarcoma.
Before speaking individually of the 13 remaining cases
of supposed 5 year cures, let us consider the criteria of
malignancy in osteogenic sarcoma. Out and out cases of
malignant osteogenic sarcoma will show every one of these
points, although occasionally one or two may be doubtful,
absent, or impossible to verify (Table 1).
History
Nearly all histories of osteogenic sarcoma cases conform to
the following ﬁve points:
1. Onset. The onset is with pain before tumor is noticed
or pathological fracture occurs. The patient may not con-
sult his physician until the tumor appears, but in that case
careful questioning will bring out the history of previous
pain, perhaps intermittent in character. History of preced-
ing trauma is frequent but always open to the question of
whether the trauma caused the lesion or only called
attention to it. Pathological fracture is common as the ﬁrst
symptom in carcinomatous metastases or in benign central
lesions as cysts and giant cell tumors, but so rare as to be
merely the exception which makes the rule in osteogenic
sarcoma. Late in the disease it is not very uncommon. We
may say therefore that unless pain precedes other symp-
toms we may suspect that the case is not one of osteogenic
sarcoma.
2. Duration. We rarely get a history of years. Not
infrequently the symptoms have existed about a year before
the patient seriously seeks medical advice, but it is very
rare that a patient allows 2 years to elapse. On the other
hand it is very unusual for a patient to seek advice before at
least a month has elapsed. The pain is usually bearable at
ﬁrst. The earliest case which we know of had had pain for a
little less than a month. In benign osteogenic tumors the
history is usually of years.
Therefore if the patient sought advice in less than a
month or over a year from the onset of symptoms we may
suspect that the case is not one of osteogenic sarcoma.
3. The general condition. Apparently bone sarcoma does
not arise in the unhealthy except after 50 in cases of Paget’s
disease of the skeleton. If the patient was in poor health at
the onset, the probabilities favor the tumor being inﬂam-
matory—tuberculosis, syphilis, osteitis, etc. Bone sarcoma
seems to be a disease of the healthy, whose repair processes
may be exuberant. This statement is not at variance with
the belief of Ewing expressed to me in conversation, that
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1persons who develop bone sarcoma may have some
essential defect in their mechanism for tissue repair. I
believe myself that these patients ‘‘repair to death’’ as
persons with hæmophilia ‘‘bleed to death.’’ That is that the
mechanism which should check repair is absent or dimin-
ished, just as in persons with hæmophilia the clotting
mechanism is abnormal. However, these sarcoma patients
almost invariably appear to be in good health.
Therefore unless the patient is considered in good health
just before onset we may suspect the case is not one of
osteogenic sarcoma.
4. Age. With the exception of cases which also have
Paget’s disease, 12 in number, we have no instances of
osteogenic sarcoma in a patient over 50. Paget’s disease
rarely occurs before 50. As recently computed by Bird and
Sosman the incidence of osteogenic sarcoma in Paget’s
disease is 12 to 14 per cent (personal communication). In
the recent Survey of bone sarcoma cases in Massachusetts
the writer concluded that the incidence of bone sarcoma is
about 1 to 100,000 in the population at one time.
Therefore in any patient over 50 who does not have
coincident Paget’s disease we may suspect the case is not
one of osteogenic sarcoma.
5. Rapidity of growth. Benign osteogenic tumors (N.B.
this does not mean benign giant cell tumor) may be
exceedingly slow in growth, the change not even being
noticeable from year to year; they may, however, have
periods of increase of growth but this is seldom rapid
enough to be noticeable month by month—rather year by
year. Inﬂammatory conditions often noticeably enlarge day
by day and very often week by week. Osteogenic sarco-
mata as a rule show steady enlargement practically always
noticeable in a month.
Therefore we may suspect that a case is not one of
osteogenic sarcoma if the enlargement has been noticeable
day by day or week by week or has not been noticeable
month by month. This statement of course excludes cases
subjected to the modern therapeutic test of radiation.
Examination
Cases of osteogenic sarcoma nearly always conform to the
following ﬁve points in examination.
1. Immobility of soft parts. Of course, this is a difﬁcult
point to determine but one in which experience readily
teaches. Rarely does an osteogenic sarcoma permit one to
feel the soft tissues roll over the bone as does a giant cell
tumor or cyst. This point is reversed in the inﬂammatory
conditions which when they have perforated the bone may
cause as much or more ﬁxation of the soft parts than
osteogenic sarcoma. Under the microscope there is a
marked increase of large vessels in the periphery about an
osteogenic sarcoma. There are often huge dilated superﬁ-
cial veins. I believe this peculiar ﬁxation of the soft parts
may be due to the ramiﬁcations of these new vessels.
Therefore we may suspect that a case is not one of
osteogenic sarcoma if there is clearly mobility of the soft
parts over the tumor.
2. Location. Approximately one-half of all osteogenic
sarcomata occur in the femur; one-quarter in the tibia; one-
half of the remainder in the other long bones. Of the other
bones in the skeleton the phalanges of ﬁngers and toes, the
carpal and most of the smaller tarsal bones appear to be
exempt. Osteogenic sarcoma is rare in the shaft of a long
bone, but this situation is the customary one for Ewing’s
tumor or for carcinomatous metastases and myeloma.
Therefore the situation of a tumor may make us suspect
that it is not an osteogenic sarcoma if it is not in one of the
known usual sites; and the suspicion is in inverse propor-
tion to the frequency of occurrence at its site.
3. Inﬂammatory signs. In exceptional cases the usual
signs of inﬂammation may occur in osteogenic sarcoma;
they are not at all unusual in cases of Ewing’s tumor.
Radiation may temporarily produce them. However, the
typical osteogenic sarcoma does not present, especially in
its early stages, pronounced fever, tenderness, redness,
leucocytosis, etc. Nevertheless these cases are usually
mistaken for osteomyelitis.
Therefore unless the signs of inﬂammation are absent or
very mild we may suspect that the case is not one of
osteogenic sarcoma.
4. Condition of neighboring joints. The dissection of
specimens of osteogenic sarcoma shows that it rarely
invades the neighboring joints until late in the course of the
disease or unless as a sequence to fracture or operation.
Joint cartilage seems to act as a barrier to both benign giant
cell tumor and osteogenic sarcoma. The latter almost
invariably proceeds actually to the cartilage while the
former often leaves a considerable amount of spongy bone
between it and the cartilage. The presence of an osteogenic
sarcoma near a joint does not involve the motion of the
joint except in proportion to the ﬁxation of the soft parts.
Such limitation as there is is not due to spasm as is the case
in inﬂammatory conditions of the joint or peri-articular
structures (unless there is fracture also).
Therefore in a case in which there is not a considerable
degree of free motion in the adjacent joints we may suspect
that the tumor is not an osteogenic sarcoma.
5. Size and shape. No early sarcoma of small size nor of
distinctly pedunculated shape has yet been registered. The
facts that they are usually well developed when ﬁrst
noticed, that they usually surround the bone or most of its
circumference; that they are as a rule both intracortical and
extracortical, that they grossly resemble callus, make the
writer feel that it is almost absurd to suppose that they start
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stood as starting in a region as callus does than in small
groups of cells. If the latter why should they grow through
the strong cortex to the other side no matter which side they
start on? At any rate thus far all gross specimens show
tumors of considerable size which are both medullary and
subperiosteal with the old cortex more or less ﬁrmly in its
old place. Pedunculated bone tumors are nearly always
benign except when congenital exostoses have been exci-
ted by trauma to efforts at repair.
Therefore if a tumor is not of considerable size or if it is
pedunculated we may suspect it is not an osteogenic
sarcoma.
The X-ray
The X-ray also furnishes us with ﬁve pretty constant
criteria.
1. Combined central and subperiosteal involvement.
Good roentgenographic pictures of osteogenic sarcomata
demonstrate this point almost as well as sagittal gross
sections. One must bear in mind, however, that superim-
posed bone outside the cortex may make the medullary
shadow irregular in density. The little cuff of reactive bone
of trumpet shape which surrounds the upper limit of the
tumor appears in the X-ray as a triangular space on each
side of the shaft under the uplifted periosteal edge. The
presence of this is a sure indication of subperiosteal ex-
tracortical involvement. It represents the last line of
defense of normal osteoblasts retreating in circular for-
mation as the tumor advances under the periosteum.
Unfortunately, the same phenomenon sometimes occurs as
a defense against inﬂammation so that this reactive triangle
in itself is not diagnostic of sarcoma. Benign tumors are
either inside or outside the old cortex. Malignant are both.
We may therefore suspect that it is not a case of oste-
ogenic sarcoma when the X-ray does not show both
medullary and subperiosteal involvement.
2. Presence of old shaft. As stated above we rarely
dissect a specimen of osteogenic sarcoma without ﬁnding
the old shaft in its normal position—even if it is in frag-
ments. It may be almost entirely destroyed in old tumors,
but even then the remaining fragments are seldom pushed
much out of place. The contrary takes place in benign giant
cell tumor which gives the appearance of distending the
bone. In Ewing’s tumor the cortex is usually widened by
the thrust of the tumor cells between the lamellæ, and old
bone may be carried somewhat to the periphery. In oste-
ogenic sarcoma the perforation of the cortex seems to be as
a rule transverse from within outward radially through the
cortex, or perhaps in the opposite direction. We have no
clue as to whether they start inside or outside the cortex. If
new bone forms it follows these radiating lines. One must
think of these radiating lines not as they show in the X-ray
as spicules but as they really are in the gross specimen as
ridges or osteophytes of irregular form on the surface of
the cortex.
Therefore if the X-ray does not show the old cortex or
fragments of it in normal position, we should suspect that
the case is not one of osteogenic sarcoma.
3. Invasive character. Dissection shows and so do our
standard series of osteogenic sarcomata that the advancing
edge of these tumors in the spongy bone is practically
never rounded and smooth as is nearly always the case
in giant cell tumors and some vascular carcinomatous
metastases. Osteogenic sarcoma advances by invasion of
the cells and the margin is irregular. Giant cell tumors and
a few vascular metastases advance by pressure atrophy due
to their pulsation as do aneurysms.
Therefore a sharp outline of the tumor against spongy
bone may make us suspect that we are not dealing with an
osteogenic sarcoma.
4. Osteolytic or osteoblastic or both. A typical X-ray of
a case of osteogenic sarcoma shows that the tumor is both
osteolytic and osteoblastic. However, in rare cases, par-
ticularly if far advanced, these tumors may be only
osteolytic or only osteoblastic. If wholly osteolytic the
suspicion of metastatic carcinoma is aroused and if wholly
osteoblastic of a benign osteogenic tumor. In most cases
characteristic radiating spicules are shown and form a very
positive sign, although exceptionally metastases or
inﬂammation may produce them. The frequency of this
sign of spicule formation is not enough to form a rule and
the absence of it is not very strong evidence against oste-
ogenic sarcoma.
Therefore unless the X-ray shows that the tumor is both
osteolytic and osteoblastic or if it shows that it is wholly
one or the other, suspicion that it is not a case of osteo-
genic sarcoma is aroused.
5. Involvement of soft parts. This is a difﬁcult point on
which to interpret the X-ray. Giant cell tumors which have
burst their capsule have frequently been interpreted as
having the soft parts involved, and yet dissection in such
cases has never shown this form of tumor as actually
invading the soft parts although it may push them aside on
fascial planes. Vice versa, the X-ray of an osteogenic sar-
coma may lead us to think it has not involved the soft parts
and dissection will show that it has. If we deﬁne the ‘‘soft
parts’’ as including the extracortical space between the
raised periosteum and the bone as shown by the ‘‘reactive
triangle’’ above alluded to at its upper limit, we may get
much help. Dissection shows that when we ﬁnd this con-
dition the tumor is always at least subperiosteal and usually
has also broken through the periosteum and begun to
invade the soft parts.
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1Therefore we may say that a tumor which does not show
in the X-ray either invasion of the soft parts or the reactive
triangle is perhaps not an osteogenic sarcoma.
Microscopic Criteria
The microscope gives also 5 pretty deﬁnite criteria com-
mon to most osteogenic sarcomata.
1. Mitoses and hyperchromatism. The relative frequency
of mitotic ﬁgures has long been a guide in estimating
malignancy in all tumors. Rapid growth in most tissues is
characterized by a relatively large number of mitoses. Like
other criteria this one has its exceptions for numerous
mitoses may occur for instance in fungating granulation
tissue and also in certain benign tumors. In benign giant
cell tumor for instance they are often quite numerous and if
an operation has been done and the wound is fungating
they are usually very numerous. On the other hand excess
of mitotic ﬁgures is a very constant ﬁnding in typical
osteogenic sarcoma. Hyperchromatism of nuclei is a par-
allel phenomenon probably equivalent to mitotic activity or
at least indicative of it. Sometimes it is seen without it and
yet it indicates it.
Therefore the ﬁnding of numerous mitoses in a bone
tumor does not necessarily indicate osteogenic sarcoma,
but absence or infrequency of mitotic ﬁgures should arouse
the suspicion that the case is not one of osteogenic
sarcoma.
2. Pleomorphism. All our instances of osteogenic sar-
coma which have run a malignant course, showed this
criterion constantly. The degree of pleomorphism is of
course a matter of individual judgment. There is a normal
range of variations of size and shape in normal cells which
it requires experience to recognize. In some cells the range
is great, for instance the endothelial leucocyte is protean in,
its ability to change in shape and size. In general a bone
tumor must be considered within normal limits of pleo-
morphism if no cells are found which cannot be duplicated
in normal inﬂammation. This is the rule in benign giant cell
tumors for none of the 100 standard tumors of this kind in
the Registry series contain even small numbers of distinctly
atypical cells. On the other hand our series of osteogenic
sarcomata all do. Ewing’s tumors are not pleomorphic and
yet are very malignant.
Probably the best single way in which to grade osteo-
genic sarcomata would be to base the prognosis on the
degree of pleomorphism. This is equivalent to expert his-
tologic opinion, for any good histologist probably bases his
opinion of the prognosis in any malignant tumor largely
on its pleomorphism, although he takes account of the
other factors as mitotic activity, hyperchromatism and
the arrangement of chromatin, nucleus and nucleolus.
However, it does not yet appear necessary to attempt to
grade osteogenic sarcoma, for our collection is not yet
large enough and as yet we cannot say bad, worse, worst.
To say Bad is enough, for after 5 years search we ﬁnd only
13 cures.
Therefore any bone tumor which does not show pleo-
morphism is probably not an osteogenic sarcoma.
3. Tumor giant cells. It is not difﬁcult to demonstrate to
a student the difference between typical tumor giant cells
and foreign body giant cells. However, occasional doubtful
giant cells are found, but very rarely are all the giant cells
in a single slide doubtful. A few individual giant cells or
small areas of foreign body giant cells are of frequent
occurrence in osteogenic sarcomata, and have little sig-
niﬁcance in diagnosis, as they probably merely indicate
hæmorrhage in the tumor. On the other hand one may
conﬁdently expect a tumor to be malignant if it contains
tumor giant cells but not necessarily to be a primary bone
tumor. Tumor giant cells may occur in cancer also but we
seldom see them in bone metastases. Then, too, many
osteogenic sarcomata show no tumor giant cells.
This criterion therefore is not universal, but we may say
that its presence in an osteogenic tumor is a very reliable
sign of malignancy; but its absence need not make one
suspicious either of the malignancy of the tumor or of its
place in the osteogenic series.
4. Differentiation. It has proved impossible to make the
differentiation toward intercellular substances as ﬁbro-
chondro-osteo-criteria of malignancy. There is an endless
variety of proportions of these intercellular substances and
an imperceptible series of gradations from one intercellular
substance to another. At most, differentiation can only be
used as a criterion of degree, the less the differentiation, in
other words the more cellular the tumor, the more malig-
nant. And now that radiation has been shown to be
effective in the inverse way it is still harder to use this
factor as a criterion. For instance Ewing’s tumor which
may be simply an undifferentiated form of osteogenic
sarcoma has nowadays with radiation a better prognosis
than a relatively well differentiated osteogenic sarcoma of
the chondro-type. Yet the relative proportion of cellular
tissue in chondromatous tumors is very important in their
prognosis, for the greater it is the worse the prognosis.
Therefore in an osteogenic tumor very complete differ-
entiation or almost no differentiation is better than
incomplete differentiation, and the evidence of quite com-
plete differentiation should make us suspect that the case is
not an osteogenic sarcoma, but a benign osteogenic tumor.
5. Tumor vessels (vascular arrangement). As this cri-
terion is my own hobby I hesitate to present it but as I have
found it very reliable even if new, I offer it for it may help
others. Early in the Registry work I noticed that the
malignant tumors had a different vascular arrangement
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capillaries or sinuses without any walls except the endo-
thelium lining them. As a contrast to this all malignant
tumors have deﬁnite branching vessels with walls of
varying thickness largely composed of tumor cells. In other
words these tumors have a perithelial arrangement as a
constant factor, and the vessels branch like the limbs or
twigs on a tree. The tumor cells hang on them like swarms
of bees, whether the cells have no intercellular substance as
in Ewing’s tumors or well developed cartilaginous material
as in some ‘‘chondrosarcomata.’’ One may see an endo-
thelial lining or perhaps a lining of tumor cells, and
immediately adjacent perithelial arrangements of cartilage
cells. Great variety of appearance of these tumor vessels is
a characteristic also.
I ﬁnd these tumor vessels a constant factor. They are
certainly useful in distinguishing giant cell tumors from the
osteogenic tumors, benign and malignant. As a criterion to
differentiate malignant from benign osteogenic tumors or
callus it again becomes a question of the individual cells
forming the walls. Benign osteogenic tumors do not have
pleomorphic cells in the vessel walls. I made one error in
considering exuberant callus malignant, on account of
somewhat atypical vessels.
My personal conviction is that every osteogenic sar-
coma shows tumor vessels and that d tumor which does not
show them in several sections is not an osteogenic
sarcoma.
Experienced pathologists have, of course, noticed these
vessels as the vascular arrangement of tumors in general,
but so far as I know they have not contrasted this vascular
arrangement with the interstitial blood supply of giant cell
tumors. Perhaps ‘‘vascular arrangement’’ is a better head-
ing than ‘‘tumor vessels’’ which I have used hitherto.
General Criteria
There are ﬁve general criteria of malignancy in a bone
tumor which seem to me important.
1. The nature of the pathological examination. For
instance the most expert pathologist will not be able to give
us as much help on the stingy bit of dried tissue handed him
by some uninterested operator, as can a keen surgeon in an
out-of-the-way clinic who has made a complete and careful
examination and description of the amputated limb.
Opinion based on careful examination of the dissected
gross specimen by a competent pathologist or by a good
surgical observer is very strong evidence for osteogenic
sarcoma. Yet it is by no means absolute.
We have two gross specimens in the Registry Collection
which have not yet been satisfactorily classiﬁed. For
example, Case 187 which is claimed as a cured case of
osteogenic sarcoma by Ewing and Coley, I have not
included in the present list although Dr. Ewing examined
the gross specimen and still possesses it. From the situation
of the tumor in the lower end of the radius and from
Dr. Ewing’s own description, I suspect it to be a variant of
giant cell tumor.
Nevertheless we may say that if the diagnosis is con-
ﬁrmed by competent examination of the gross specimen it is
one of the strongest but not an absolute criterion. If other
important criteria do not agree, the suspicion is aroused
that the tumor is not an osteogenic sarcoma. Furthermore
histological reports even by excellent pathologists on small
and imperfect exploratory specimens should not be
accepted unless in agreement with other important criteria.
2. The quality of the data. What has been said in regard
to the character of the pathological data applies to the other
data. A history taken by someone interested in the patient
or in the bone sarcoma problem is likely to be much more
fruitful than if carelessly taken by someone interested in
neither. Our best histories have come from either the small
hospitals where the patient is of paramount interest or from
the occasional man in some large clinic who is interested in
bone tumors.
The character of the roentgen data is of great impor-
tance. There is a deplorable tendency to neglect technique
in bone cases. The greatest possible detail is needed and if
attained, may be of more importance to the patient than the
surgeon’s knife. Undoubtedly we must look to the roent-
genologist to ﬁnd the criteria of diagnosis at the early stage
when pain has begun and tumor has not yet appeared.
We may say then that the quality of the data has much to
do with our conviction of the diagnosis of osteogenic
sarcoma.
3. Unanimity of the different specialists. In typical
instances of osteogenic sarcoma the clinician, the roent-
genologist, the operator, and the pathologist all arrive
independently at the same diagnosis. As our experience
progresses and knowledge diffuses, this rule becomes more
striking.
A patient entering a hospital which has cooperated in the
work of the Registry will probably have his bone tumor
independently diagnosed by the different departments. If
one has doubt, all should have and probably actually have.
General agreement however will be the rule.
To express this differently, any hospital which is doing
its best for cases of bone tumor will promptly diagnose the
majority of cases of osteogenic sarcoma independently in
each department concerned and the synthesis of these
opinions and the action to be taken on them will be the
responsibility of someone familiar with the work of the
Registry.
4. The Registry classiﬁcation. A criterion of more or less
value in regard to the diagnosis of a case of osteogenic
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1sarcoma is whether or not it has been so accepted by the
Registry Committee. This is neither ﬁnal nor fundamental
and merely represents the best obtainable collection of
opinions on such data as is furnished at a given date. Any
hunter knows the difﬁculty of distinguishing game running
through the woods. An idea of the height of the animal is
obtained at one glance, the ﬂash of a white tail at another,
and the outline of horns at a third. The conviction that a
deer has passed may be arrived at, but the story the hunter
tells will be believed in proportion to his own experience
and standing in intellectual honesty. At that, he may be
mistaken.
Expert opinion would not be expert opinion if as a rule it
were capable of proof. The relative importance of the
criterion of the Registry Classiﬁcation is of this degree and
varies with the character of the data and of the Committee.
The entity of osteogenic sarcoma has been recognized
by a group, as hunters recognize a rare animal by repeated
glimpses in all degrees of perfection, from a ﬂash through
the woods to the slaughtered, dissected, stuffed, macerated,
dried, bottled, or serially sectioned individual. One hunter
who might recognize the fossil vertebræ of the animal
might not recognize the living creature darting through the
woods. The practical hunter would, although he might
confuse it with one of an allied species. The Registry
Committee has had the advantage of being aided by much
expert help and by varied points of view from different
individuals. It has succeeded in establishing this entity and
describing its characteristics but in individual cases it may
be mistaken on ﬂeeting glimpses. The 13 cases here sub-
mitted are of this character. It is our belief that they were
instances of osteogenic sarcoma, but we ourselves recog-
nize the possibility of error.
In our series of 200 standard osteogenic sarcomata
nearly 50 per cent are still living under the 5 year limit. We
feel much more sure of the correctness of diagnosis in most
of these cases than in the 13, although in many much of the
outline was behind the trees.
5. The ultimate result. It is easy to say that the. Com-
mittee modify their diagnoses when they know the result.
This is true; we do, so far as we can, but in many cases we
do not yet know the result. We have also been criticized for
letting each expert see the opinions of those given before
him. We are in fact glad to have him do so. We want every
bit of information and advice we can get, and so should
every expert. It can do no harm, for we realize that on such
data as we get, this writing of opinions is often merely an
amusing mental exercise.
To be sure there is a serious side when we think of
how many unregistered cases of bone sarcoma do not
even get the beneﬁt of the opinion of the Registrar which
is freely given for rich or poor and always should be. In
our hospitals, decisions in cases of bone sarcoma are often
made on less experience than that which even a newly
appointed Registrar would have at his command. Very
few pathologists or surgeons see 10 cases of this lesion in
their whole professional careers, where the diagnosis is
deﬁnite and the outcome known. A new Registrar who has
studied this series of 650 cases could certainly be of help
to anyone on whom the responsibility of decision of life
and limb rests.
But we must confess that even the most experienced after
the study of all the 650 registered cases must sometimes
modify his diagnosis by the ultimate result. If a case
diagnosed as osteogenic sarcoma does not die within
5 years with metastases in the lungs all criteria should
again be scrutinized with the greatest care.
Part II.—The 13 Cases of 5-year Cures of Osteogenic
Sarcoma
As most of these cases have already appeared in the liter-
ature I will merely give references and discuss a few points
in each.
CASE 29. This case has never been published in detail. It
was that of a boy of 14 with a tumor of the upper end of the
tibia. He was the nephew of an able surgeon who recog-
nized the seriousness of the lesion within 6 weeks of onset
and promptly did a thigh amputation. It is perhaps the
record for prompt diagnosis and treatment. The patient has
been well for 9 years. An interesting feature of this case
was that postoperative treatment was conducted by Dr.
James B. Murphy of the Rockefeller Institute on his theory
derived from experiments in animals that a mild lympho-
cytosis repeatedly aroused by light, diffuse doses of the
roentgen ray prevents experimental inoculation of tumors
in animals and, therefore, might prevent the growth of
small metastases in the human being.
There are several of our criteria lacking in this case, for
instance the onset was with trauma not pain; the history a
matter of weeks rather than months; no X-rays or gross
specimen have been preserved; the hyperchromatism is not
great nor are single mitoses very frequent. In fact the
diagnosis is largely based on the extreme pleomorphism of
the cells, the presence of many typical tumor giant cells
with multiple mitoses and Dr. Mallory’s original written
report on the gross specimen. There is general agreement
among the pathologists.
CASE 50. See Binnie’s Surgery, vol. iii, p. 456.
This was a man of 44 with a very large tumor of the
lower end of the femur. The case lacks some very impor-
tant criteria. The age, 44, was exceptional. There was little
pain, and tumor was the ﬁrst symptom. The tumor had been
present 3 years at least. It had differentiated largely to
cartilage and bone, and there was little cellular tissue.
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gross specimen. The diagnosis rests wholly on a few small
areas which show a cellular growth with some mitotic
activity and pleomorphism. Yet there is agreement among
the pathologists on grading this as an osteogenic sarcoma
rather than a benign or borderline chondroma. There are
typical tumor giant cells.
The history, however, is strongly against this being a
real case of osteogenic sarcoma. ‘‘Patient has always been
well except as to his left knee on which 3 years ago he
ﬁrst noticed a small lump on the outer side; this, patient
says, was movable. Patient indicated that this was at the
summit of the external condyle of the left femur. He
knows of no injury save a slight blow at this point
received some weeks before the lump was noticed. The
lump has grown pretty continuously ever since, although
being stationary at times. It has never receded; has never
been painful but was tender at one spot on the upper
side of the patella. There is some tenderness in walking.
Patient says that he has rather gained weight recently than
lost.’’
Patients with osteogenic sarcoma of the femur do not
usually walk 3 years without pain and gain weight. This is
the exception which proves the rule unless the histological
malignancy in this case is the exception which proves
another rule.
CASE 64. This case was reported by Wells. Neither gross
specimen nor X-ray was preserved. There were marked
inﬂammatory signs. Repeated operations were done which
might well have diffused metastases.
The diagnosis is based on expert opinion on the slides
and is not strongly positive for most of the tissue is obvi-
ously inﬂammatory. While agreeing in the diagnosis, there
is evident doubt among all the pathologists.
CASE 100. After two incomplete operations the thigh was
amputated. She was also treated by Coley toxins and
radiation.
This case fulﬁlls all the criteria with the possible
exception of differentiation. The tumor is so well differ-
entiated that the sections closely resemble callus.
Otherwise than this and the survival after so much surgery,
the case seems a typical osteogenic sarcoma.
CASE 101. The questionable features in this case were of
its inﬂammatory nature; onset by ﬁxation of joint rather
than pain; the presence of many of the signs of inﬂam-
mation clinically and in the sections; involvement of joint.
No X-ray is preserved and the character of the data is
unsatisfactory. There is no agreement on classiﬁcation
among the pathologists except on the histological malig-
nancy. There is a question whether the tumor does not
belong in the myeloma series.
CASE 102. No X-ray is preserved. The data in general are
unsatisfactory. There is no good gross description of speci-
men but the histology ispretty typicalofosteogenicsarcoma.
CASE 172. The one favorable feature is Ewing’s
description of the amputated leg: ‘‘Shows early and
unusually limited central and subperiosteal osteogenic
sarcoma.’’
CASE 184. The sections resemble a very cellular osteitis
ﬁbrosa and some of the pathologists class it as such. The
Table 2. Five year cures—thirteen cases
Case Reg’st’d by Name Age Bone Previous
partial ops.
Date amp. Date last
report
Toxins Radiation Reported in
29 Hubbard S. 14 Tibia 0 6-23-16 June, 1925 0 0 Never reported
50 Rixford O. 44 Femur 0 1-22-09 Oct., 1924 0 0 Binnie’s Surgery, vol. iii,
p. 456
64 Wells B. 19 Femur + 8-5-09 June, 1925 0 0 Surg., Gynec. & Obst, 1922,
May, p. 698
100 Bloodgood
& Coley
P. 23 Femur + Aug., ’17 April, 1925 + + To be reported by Coley
101 Bloodgood N.T. 24 Femur 0 7-8-13 May 16, ’24 0 0 J. Radiol., 1920, Mar., p. 149
102 Bloodgood B. 11 Tibia + May, ’13 April, 1925 ? ? J. Radiol., 1920, Mar., p. 148
172 Coley S. 19 Femur ? Aug., ’20 April, 1925 + + To be reported by Coley
184 Coley T. 26 Femur 0 8-20-16 Jan., 1924 + + To be reported by Coley
261 Thompson M. 11 Femur 0 4-8-16 Oct., 1924 0 0 Surg. Clin. of North America,
1922, Oct.
408 Coley D. 18 Femur + 4-7-06 April, 1925 + 0 To be reported by Coley
501 Bloodgood S. ? Femur + 1-18-13 June, 1924 ? Not reported
586 Coley F. 48 Femur + 10-31-16 April, 1925 + + To be reported by Coley
183 Coley St. Tibia Not amputated + + To be reported by Coley
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1Committee, however, feels that it should be classed as a
sarcoma. Mitosis and hyper-chromatism are not marked
and differentiation is pretty complete. We have no X-ray
and in such a case the X-ray would mean much.
CASE 261. This case has every unfavorable character
except that the tumor was pretty well conﬁned beneath the
periosteum and in the center of the bone. Histologically it
was very malignant. Amputation was done without
exploratory incision and there was no after treatment. It is
in my opinion the most typical and also the most complete
case in the series. It shows surgery at its best.
CASE 408. The character of the exploratory operation
through the joint rendered the prognosis very unfavorable.
We have no good report of the gross specimen or X-ray.
However, there can be little doubt from the description of
the operation and the histology that this was a malignant
tumor. It hardly seems as if amputation alone could have
cured in this case. No radiation was used according to our
notes; the mixed toxins were used. Compare the preceding
case in which no exploration was done or after treatment
given.
Although the pathologists agree that this case was
malignant the histology is unsatisfactory for classiﬁcation.
CASE 501. The notes on this case are very inadequate.
There is no real history, no X-ray, and the histology is
barely adequate to include it in this group. Several
pathologists have raised the question of its being a giant
cell tumor. Complete data, even one good X-ray, would
probably expel all doubt.
CASE 586. This case is well registered with X-rays,
photos, and slides but it is really not one of the true
osteogenic sarcomata. ‘‘Had fractured femur at 4 and 11.
At 21 had slight periostitis at site of fracture.’’ In
August, 1916, when 48 years old, he had a tumor of the
femur at the site of one of the fractures. He was treated
by curettage, X-ray, radium, and toxins for several
months, and the thigh amputated October, 1916. Wellin
April, 1925. There was a fairly circumscribed mass at
the site of the fracture and an open granulating wound
over it. Histologically it is a sarcoma. There is doubt
among the pathologists as to whether it should be clas-
sed as an osteogenic sarcoma at all or as a ﬁbrosarcoma
arising in scar tissue.
CASE 183. This case is the only one in which amputation
did not contribute to the success which must have been due
to radiation or toxins or both. It has been and will be again
reported by Dr. Coley in full. It is a unique, remarkably
encouraging case, for the limb was saved and metastases in
the glands of the groin receded and did not reappear.
Logically the mixed toxins and radiation must share the
credit. There is an almost equally brilliant case, 267,
among the Ewing tumors, also treated by radiation and
toxins.
Summary
One must realize that the cases here presented are by no
means the only possible 5 year cures of osteogenic sarco-
mata in the Registry series. It would be better to say that
they are the 13 most authentic ones. Other cases especially
Case 187 should perhaps also be included and discussed,
but there is a limit to interest in the subject if too doubtful
instances are brought into question.
I have done my best to be judicial in selecting these, and
my colleagues, Doctors Bloodgood and Ewing, have
agreed with me that these are the best representatives of
cured osteogenic sarcomata and even these are pretty
doubtful. If it had not been for Coley’s enthusiasm and
optimism we should have few to record. Coley has shown
us at least that cases considered hopeless may be cured.
Even if the hopelessness was due in some cases to the
errors of pathologists in mistaking benign tumors for
malignant ones, Coley’s optimism has been well justiﬁed.
Whether or not the evidence also justiﬁes his faith in the
use of mixed toxins is an academic matter compared with
the bald facts that he can furnish evidence of the cure of
apparently hopeless cases, and that he has furnished evi-
dence of nearly as many cures as all the other surgeons of
the country together. He has also furnished evidence of
more cures than shown in the above list but some of these
other cases are considered by our Committee to be
instances of benign giant cell tumor.
From a logical standpoint it seems to me that argument
as to the value of the toxins should rest on their postop-
erative use, for the fact is that over one-half of the
successful cases following amputation have had the post-
operative use of this agent. To be sure there are few in all.
Further evidence of the value of the mixed toxins will
appear in Conner’s paper on Ewing’s tumor in the Archives
of Surgery, but as in these cases there was confusion owing
to coincident use of radiation.
Of the present series of 13, in 5 cases amputation must
be given the credit alone, unless the Murphy method of
diffuse X-ray is claimed to share one of these (Case 29).
This idea of Murphy’s seems to me to deserve more
extended trial.
In two other cases (102 and 501), we do not know
whether the toxins were used or not.
In 5 cases they were used before or after operation but in
only one of these was radiation not used also.
Finally, in 1 case the cure must be credited to either
toxins or radium or both. This case was unique in many
respects but clearly histologically malignant.
Another point brought out is interesting. In only 5 cases
was the amputation done at the same time as the explora-
tion. In the other 7, exploration was done at least once and
in some cases several times before amputation. Even if
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caused diffusion of the tumor.
In only 1 case was the amputation done without pre-
liminaryincisionbutthiswasthemosttypicalmalignantcase.
These facts speak in two ways, either against the
malignancy of these particular tumors or in favor of
exploration being a harmless procedure.
I have presented what I believe to be the best evi-
dence of 5 year cures so far collected by the Registry.
We can continue to guess on the strength of these
meager facts or we can co-operate to collect a more
complete series.
Shall the College continue the Registry of Bone
Sarcoma?
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